Tacrolimus, Sirolimus and Everolimus Doses in HIV-Infected Solid-Organ Recipients, Requiring a Cobicistat-Based Antiretroviral Regimen: Report of Three Cases and Review | SpringerLink
Early conversion of pediatric kidney transplant patients to everolimus with reduced tacrolimus and steroid elimination: Results of a randomized trial - American Journal of Transplantation
![PDF] Introduction of everolimus in kidney transplant recipients at a late posttransplant stage | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/52b7f3e549ab8e70c2079418becddcf9e9535b89/3-Table1-1.png "PDF] Introduction of everolimus in kidney transplant recipients at a late posttransplant stage | Semantic Scholar")
PDF] Introduction of everolimus in kidney transplant recipients at a late posttransplant stage | Semantic Scholar
An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients - ScienceDirect
IJMS | Free Full-Text | Effects of NR1I2 and ABCB1 Genetic Polymorphisms on Everolimus Pharmacokinetics in Japanese Renal Transplant Patients
Everolimus dose and trough blood levels, and laboratory values for... | Download Scientific Diagram
Study design. Steroid dose will be at least 5 mg prednisolone or... | Download Scientific Diagram
Full article: The use of everolimus in renal-transplant patients
Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities | Nefrología
Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities | Nefrología
Article: Conversion from tacrolimus to everolimus with complete and early glucocorticoid withdrawal after kidney transplantation: a randomised trial (full text) - January 2018 - NJM
Article: Conversion from tacrolimus to everolimus with complete and early glucocorticoid withdrawal after kidney transplantation: a randomised trial (full text) - January 2018 - NJM
Enhanced Humoral Immune Response After COVID-19 Vaccination... : Transplantation
Transplantology | Free Full-Text | Dyslipidemia in Renal Transplant Recipients
Everolimus with Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplant Recipients: Efficacy and Safety Outcomes from the TRANSFORM Study - ATC Abstracts
Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial - The Lancet
Everolimus with Reduced-Dose Calcineurin Inhibitor versus Mycophenolate with Standard-Dose Calcineurin Inhibitor in De Novo Kidney Transplant Recipients: Renal Function Results from the TRANSFORM Study - ATC Abstracts
Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen—Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil | PLOS ONE
Figure 1 from Efficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant Recipients | Semantic Scholar
De Novo Therapy with Everolimus and Low-Dose Calcineurin Inhibitors in Kidney Transplantation | Semantic Scholar
Use of everolimus in liver transplantation
Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de
